The propensity of complement to damage self is controlled by expression of regulatory proteins. Recent results demonstrate that deleting just one of these regulators in mice causes complement to attack and destroy the embryo. These findings may have relevance to human pregnancy.
The complement system, a major component of innate immunity, comprises a group of 15 plasma proteins that combine in a targeted proteolytic cascade to kill pathogens [1] . Complement can kill by directly lysing some pathogens, notably several clinically relevant strains of bacteria. Of greater importance, however, is its role in attracting, targeting and priming phagocytic cells for clearance of pathogens, and in marking these pathogens for destruction. The third component, C3, lies at the heart of the complement system, acting as a pivot to link the recognition and effector arms of the complement cascade. C3 constantly undergoes low-level spontaneous activation -'tickover' -ensuring immediate activation on the surface of pathogens.
Tickover activation occurring in vivo presents a serious threat to host cells which, given the potential for rapid amplification within the complement cascade, must find ways to guard themselves against the consequences of complement attack on their surfaces (Figure 1 ). Several membrane proteins have evolved to provide host cells with the protection they need to control the body's own complement, hence preventing damage to self [2] . In humans, a group of three cell membrane proteins perform this complement regulatory function: decay accelerating factor (DAF, or CD55) and membrane cofactor protein (MCP, or CD46) both act early in the complement cascade to control C3 activation, while CD59 acts later in the cascade to prevent formation of the lytic lesion generated by the membrane attack complex [3] .
Rats and mice produce all three of the membrane complement regulators described in humans, albeit with quite different patterns of distribution. They also produce an additional, broadly distributed complement regulator not found in other species, known as Crry [3] . Crry is structurally similar to MCP and DAF, and has similar complement inhibitory activities. It is clear from experiments of Okada and co-workers [4] that Crry is a key complement regulator in rats: systemic blockade of Crry using F(ab) fragments of a blocking monoclonal antibody caused spontaneous complement activation and a severe shock syndrome. Similarly, injection of anti-Crry antibody fragments into skin caused local activation of complement and inflammation [5] .
Like rat Crry, mouse Crry is a broadly distributed and powerful inhibitor of complement in vitro [6] . But its functional relevance in vivo has not been examined. The acid test of the in vivo relevance of a complement regulator is to remove it and then to see what happens. This is essentially what was done in the antibody blocking experiments described above, but another and perhaps more effective way to do this is by gene deletion. In mice, the gene encoding the most abundant form of DAF -mice have two DAF genes -has been deleted with relatively little consequence [7] .
When Molina and colleagues [8] undertook to delete the gene encoding Crry in mice, it is likely that they expected a phenotype similar to that of the DAF knockout. Instead, they discovered that homozygous Crry -/-mice died in utero: Crry -/-embryos did in fact survive in the expected frequencies until some 9.5 days post coitus but, beyond this, survival rapidly declined with death resulting from developmental arrest. By contrast with wild-type embryos, Crry -/-embryos appeared to contain C3 deposited on the placenta, indicating that complement had been activated at this site. Again by contrast with wild-type embryos, there was a marked invasion of inflammatory cells into the placental tissue of Crry -/-embryos. This provided additional and compelling evidence that, in the absence of complement regulation by placental Crry, embryos had died as a consequence of complement activation in the placenta. Deposition of antibody and of other complement components in Crry -/-placenta was not examined, making it impossible to state precisely how complement was activated.
To check that spontaneous activation of complement was indeed responsible for the loss of Crry -/-embryos, Molina and colleagues [8] hit on the clever idea of introducing the Crry mutation onto a C3 deficient background, by crossing the heterozygotes with C3 -/-mice [9] . This 'rescue' strategy was spectacularly successful. On the C3 -/-background, characterised by an absence of C3 protein, Crry -/-mice survived gestation and were born healthy. Taken together, the data convincingly demonstrate that there is ongoing complement activation at the fetomaternal interface which must be held in check by complement regulators. Molina and colleagues [8] state that MCP is not expressed in mouse placenta, and that DAF is expressed only in late embryos. It therefore appears that Crry alone protects the mouse embryo from complement attack.
So what does all this mean for human pregnancy? The journey from conception to birth is fraught with danger. It has been estimated that between 50 and 70% of all conceptions fail. Although a majority of these are unrecognised, some 15% of recognised pregnancies are lost and some 1-2% of women suffer three or more consecutive miscarriages (recurrent spontaneous abortions) [10] . Complement deposition has been described in preeclampsia, a syndrome associated with placental failure [11] . However, the contribution of innate immunity, and specifically complement activation, to all these pathologies remains largely unexplored. Despite this, all three of the known human membrane regulators -DAF, MCP and CD59 -have been found in abundance in the human placenta [12] [13] [14] . On the basis of their characteristic distribution patterns, it has already been argued that these proteins are strategically positioned to protect the placenta from complement activation [12, 13] .
Rare individuals deficient in DAF or CD59 have been reported, but no MCP-deficiencies have been found [15, 16] . DAF-deficient individuals had no clear phenotype, and the single CD59-deficient individual had a severe hemolytic and thrombotic syndrome resembling paroxysmal nocturnal hemoglobinuria. On the face of it, the fact that individuals lacking DAF or CD59 have survived pregnancy apparently unscathed makes it unlikely that either regulator alone is essential for fetal survival. It is tempting to speculate that the failure to find individuals deficient in MCP, a key regulator of the alternative complement pathway, might suggest an essential role for this protein, perhaps in protecting the placenta. On the other hand, it is equally possible that these individuals have not been found because the deficiency is without consequence. Apart from complete deficiencies, more subtle alterations in complement regulation within the placenta might also contribute to placental dysfunction and miscarriage.
Where do we go from here? As a first step, we believe it is essential that evidence for complement activation in association with fetal loss and placental pathology should be sought at every opportunity, in order to establish if complement plays a role in some cases of placental failure and miscarriage. This needs to be done urgently because effective strategies for inhibiting complement are now available. Powerful systemic inhibitors of complement, often derived from the natural membrane regulators, have been developed for therapy of complement-mediated disease. Of these, a soluble recombinant form of complement receptor 1 (sCR1) has been most widely used [17, 18] . The mice studied by Molina and colleagues [8] might well have been maintained to term by the simple strategy of inhibiting complement by administering sCR1 to the mother. It seems reasonable to propose that, in 'Tickover' activation of complement and protection of the placenta. (a) C3b is continually deposited on all plasma-exposed surfaces in the body. On a surface that lacks natural protective factors (labelled 'activating surface'), amplification occurs with the deposition of more C3b and other components and release of anaphylatoxins C3a and C5a. The anaphylatoxins attract phagocytic cells to the site where they bind the complement-coated surface and initiate tissue destruction. (b) Tickover activation occurs on the placental trophoblast, but expression of complement regulators inhibits amplification. In the mouse, the recent work of Molina and colleagues [8] shows that Crry is crucial to this inhibition. In humans, it is likely that MCP and DAF work together to provide the necessary control.
humans, complement-mediated placental damage might also be prevented by using sCR1 or similar agents [19] .
The elegant study of Molina and colleagues [8] focuses attention once again on the problem highlighted by Peter Medawar almost 50 years ago: how does the fetus avoid rejection by the mother's immune system? The mechanisms underlying this tolerance have intrigued immunologists and no comprehensive explanation has yet emerged [20, 21] . Most work has focussed on adaptive immune mechanisms -antibodies and T cells. Here we return to the biologically older, but equally effective, innate immune system in which complement is a major player. Molina and colleagues' work suggests that the placenta is attacked by complement, but survives by virtue of expression of a protective protein. It is likely that a similar situation pertains in humans and, hence, that a failure to protect against complement may contribute to placental pathology. It will indeed be gratifying if studies aimed at bettering our understanding of the basic aspects of complement biology lead to the emergence of novel approaches to the treatment of pregnancy disorders.
